MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Met, metastasis, motility and more

Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652

Circular binary segmentation for the analysis of array-based DNA copy number data

Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. H. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,304

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 966

Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation

Stahlhut, C. E., & Slack, F. J. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1003008 · Cited by 147

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

Schwaederle, M. C., Patel, S. P., Husain, H., Ikeda, M., Lanman, R. B., Banks, K. C., Talasaz, A. H., Bazhenova, L. A., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2497 · Cited by 146

MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation

Rho, J. K., Choi, Y. J., Kim, S. Y., Kim, T. W., Choi, E. K., Yoon, S.-J., Park, B. M., Park, E., Bae, J. H., Choi, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1103 · Cited by 144

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

Dietel, M., Jöhrens, K., von Laffert, M., Hummel, M., Bläker, H., Pfitzner, B. M., Lehmann, A., Denkert, C., Darb‐Esfahani, S., Lenze, D., et al. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.39 · Cited by 150

Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling

Yi, Y., Zeng, S., Wang, Z., Wu, M., Ma, Y., Ye, X., Zhang, B., & Liu, H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.12.021 · Cited by 145

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

Kubo, T., Yamamoto, H., Lockwood, W. W., Valencia, I., Soh, J., Peyton, M., Jida, M., Otani, H., Fujii, T., Ouchida, M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24150 · Cited by 143

Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

Onitsuka, T., Uramoto, H., Nose, N., Takenoyama, M., Hanagiri, T., Sugio, K., & Yasumoto, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.022 · Cited by 142

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143

Drug discovery in advanced prostate cancer: translating biology into therapy

Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 143

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures

Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 142

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Fassunke, J., Müller, F., Keul, M., Michels, S. Y. F., Dammert, M. A., Schmitt, A., Plenker, D., Lategahn, J., Heydt, C., Brägelmann, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07078-0 · Cited by 143

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins

Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 137

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Koeppen, H., Yu, W., Zha, J., Pandita, A., Penuel, E. M., Rangell, L. K., Raja, R. G., Mohan, S., Patel, R., Desai, R. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1836 · Cited by 136

Targeting the c-MET signaling pathway for cancer therapy

Liu, X., Yao, W., Newton, R. C., & Scherle, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.7.997 · Cited by 134

Targeting the Adaptability of Heterogeneous Aneuploids

Chen, G., Mulla, W. A., Kucharavy, A., Tsai, H.-J., RUBINSTEIN, B. Y., Conkright, J. J., McCroskey, S., Bradford, W. D., Weems, L., Haug, J. S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.026 · Cited by 135

Novel Therapeutic Targets in Non-small Cell Lung Cancer

Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 133

Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Casás‐Selves, M., Kim, J., Zhang, Z., Helfrich, B. A., Gao, D., Porter, C. C., Scarborough, H. A., Bunn, P. A., Chan, D. C. F., Tan, A. C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2848 · Cited by 132

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 131

Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells

Karagonlar, Z. F., Koç, D., İşcan, E., Erdal, E., & Atabey, N. (2016) · Cancer Science · doi:10.1111/cas.12891 · Cited by 132

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment

Owusu, B. Y., Galemmo, R. A., Janetka, J. W., & Klampfer, L. (2017) · Cancers · doi:10.3390/cancers9040035 · Cited by 140

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs

Choi, H. Y., & Chang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713618 · Cited by 143

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

Davies, K. D., Mahale, S., Astling, D. P., Aisner, D. L., Le, A. T., Hinz, T. K., Vaishnavi, A., Bunn, P. A., Heasley, L. E., Tan, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082236 · Cited by 128

Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer

Togashi, Y., Masago, K., Fukudo, M., Terada, T., Fujita, S., Irisa, K., Sakamori, Y., Kim, Y. H., Mio, T., Inui, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e2138b · Cited by 130

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Johnson, M. L., Yu, H. A., Hart, E. M., Weitner, B. B., RADEMAKER, A. W., Patel, J. D., Kris, M. G., & Riely, G. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7328 · Cited by 130

Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non‐Small‐Cell Lung Cancer

Kosaka, T., Yamaki, E., Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/165214 · Cited by 130

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

Wang, Z., Chen, R., Wang, S., Zhong, J., Wu, M., Zhao, J., Duan, J., Zhuo, M., An, T., Wang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110780 · Cited by 130

N-Cadherin Expression Is Associated with Acquisition of EMT Phenotype and with Enhanced Invasion in Erlotinib-Resistant Lung Cancer Cell Lines

Zhang, X., Liu, G., Kang, Y., Dong, Z., Qian, Q., & Ma, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057692 · Cited by 129

Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology

McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 131

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

Lee, J. J.-K., Shin, J. Y., Kim, S., Lee, S., Park, C. C., Kim, J. Y., Koh, Y., Keam, B., Min, H. S., Kim, T. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt127 · Cited by 130

Molecular cancer therapy: Can our expectation be MET?

Migliore, C., & Giordano, S. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.022 · Cited by 129

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

Minuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O’Brien, T., Mendoza, A. D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.335 · Cited by 127

A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment

Taube, S. E., Clark, G. M., Dancey, J. E., McShane, L. M., Sigman, C. C., & Gutman, S. I. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp334 · Cited by 152

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

Scagliotti, G. V., Novello, S., Schiller, J. H., Hirsh, V., Sequist, L. V. D., Soria, J., von Pawel, J., Schwartz, B. E., von Roemeling, R., & Sandler, A. B. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.003 · Cited by 126

EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis

Breindel, J. L., Haskins, J. W., Cowell, E. P., Zhao, M., Nguyen, D. X., & Stern, D. F. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3775 · Cited by 126

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

Xie, Q. R., Bradley, R., Kang, L., Koeman, J. M., Ascierto, M. L., Worschech, A., Giorgi, V. D., Wang, E., Kefene, L., Su, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119059109 · Cited by 128

Molecular Pathology of Primary Non-small Cell Lung Cancer

Suster, D. I., & Mino-Kenudson, M. A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.08.004 · Cited by 130

Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)

Reungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 127

A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization

Hensing, T. A., Chawla, A., Batra, R., & Salgia, R. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8778-4_5 · Cited by 127

Targeted therapy for non-small-cell lung cancer: past, present and future

Forde, P. M., & Ettinger, D. S. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.47 · Cited by 123

How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers

Politi, K. A., & Pao, W. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 126

Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer

Kleczko, E. K., Kwak, J., Schenk, E. L., & Nemenoff, R. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00954 · Cited by 122

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

Liang, H., & Wang, M. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s231257 · Cited by 123

Acquired resistance to drugs targeting receptor tyrosine kinases

Rosenzweig, S. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.025 · Cited by 122

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

Janjigian, Y. Y., Azzoli, C. G., Krug, L. M., Pereira, L. K., Rizvi, N. A., Pietanza, M. C., Kris, M. G., Ginsberg, M. S., Pao, W. J., Miller, V. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2662 · Cited by 124

Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment

Buettner, R., Wolf, J., & Thomas, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9867 · Cited by 123

MET as a target for treatment of chest tumors

Cipriani, N. A., Abidoye, O. O., Vokes, E. E., & Salgia, R. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.011 · Cited by 120

Treatment of kidney cancer

Kaelin, W. G. (2009) · Cancer · doi:10.1002/cncr.24232 · Cited by 120

EGFR Signals Downregulate Tumor Suppressors miR-143 and miR-145 in Western Diet–Promoted Murine Colon Cancer: Role of G1 Regulators

Zhu, H., Dougherty, U., Robinson, V. L., Mustafi, R., Pekow, J. R., Kupfer, S. S., Li, Y.-C., Hart, J. A. L., Goss, K. H., Fichera, A., et al. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0531 · Cited by 118

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

Hirsch, F. R., Janne, P. A., Eberhardt, W., Cappuzzo, F., Thatcher, N., Pirker, R., Choy, H., Kim, E. S., Paz-Ares, L. G., Gandara, D. R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ed0ff · Cited by 122

Head neck squamous cell carcinoma c‐Met+ cells display cancer stem cell properties and are responsible for cisplatin‐resistance and metastasis

Sun, S., & Wang, Z. (2011) · International Journal of Cancer · doi:10.1002/ijc.25927 · Cited by 125

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors

Sun, J., Ahn, M., Choi, Y., Ahn, J. S., & Park, K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.023 · Cited by 121

Molecular Pathology of Non–Small Cell Lung Cancer

Aisner, D. L., & Marshall, C. B. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpfr12wjkceezz · Cited by 119

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

Lai, G. G. Y., Lim, T. H., Lim, J., Liew, P. J. R., Kwang, X. L., Nahar, R., Aung, Z. W., Takano, A., Lee, Y. Y., Lau, D. P. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00177 · Cited by 118

The role of the c-Met pathway in lung cancer and the potential for targeted therapy

Sattler, M., Hasina, R., Reddy, M. M., Gangadhar, T. C., & Salgia, R. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011408636 · Cited by 117

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

Camidge, D. R., Barlési, F., Goldman, J. W., Morgensztern, D., Heist, R. S., Vokes, E. E., Spira, A. I., Angevin, E., Su, W., Hong, D. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00739 · Cited by 117

Impact of EGFR mutation analysis in non-small cell lung cancer

Yamamoto, H., Toyooka, S., & Mitsudomi, T. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.021 · Cited by 116

The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non–small Cell Lung Cancer Cells

Milligan, S. A., Burke, P., Coleman, D. T., Bigelow, R. L. H., Steffan, J. J., Carroll, J. L., Williams, B. J., & Cardelli, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0109 · Cited by 118

BRAF, a target in melanoma

Flaherty, K. T., & McArthur, G. A. (2010) · Cancer · doi:10.1002/cncr.25261 · Cited by 118

Lung cancer molecular epidemiology in China: recent trends.

Zhou, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.09.01 · Cited by 115

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

Rothschild, S. I. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 117

EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

Sholl, L. M., Xiao, Y., Joshi, V. A., Yeap, B. Y., Cioffredi, L., Jackman, D. M., Lee, C., Janne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 116

HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors

Gusenbauer, S., Vlaicu, P., & Ullrich, A. (2012) · Oncogene · doi:10.1038/onc.2012.396 · Cited by 115

Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy

Huang, S., van Duijnhoven, S. M. J., Sijts, A. J. A. M., & van Elsas, A. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03404-6 · Cited by 118

Signaling cross-talk in the resistance to HER family receptor targeted therapy

Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 118

MicroRNA-214 Regulates the Acquired Resistance to Gefitinib via the PTEN/AKT Pathway in EGFR-mutant Cell Lines

Wang, Y.-S., Wang, Y., Xia, H., Zhou, S., Schmid‐Bindert, G., & Zhou, C. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.1.255 · Cited by 114

C-MET inhibitors for advanced non-small cell lung cancer

Pasquini, G., & Giaccone, G. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1462336 · Cited by 119

Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways

Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-30158-6 · Cited by 117

Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

Keam, B., Kim, D.-W., Park, J. H., Lee, J.-O., Kim, T. M., Lee, S.-H., Chung, D. H., & Heo, D. S. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0602-1 · Cited by 113

Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer

Gadgeel, S. M., & Wozniak, A. J. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.12.001 · Cited by 116

Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play

Patel, G. K., Chugh, N., & Tripathi, M. (2019) · Cancers · doi:10.3390/cancers11101405 · Cited by 121

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights

Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 119

Importance of STAT3 signalling in cancer, metastasis and therapeutic interventions

El‐Tanani, M., Khatib, A. O. A., Aladwan, S., Abuelhana, A., McCarron, P. A., & Tambuwala, M. M. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110275 · Cited by 115

Dr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer

Pavelka, N., Rancati, G. I., & Li, R. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.06.003 · Cited by 110

Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2

Grüllich, C. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_5 · Cited by 110

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing

Schwaederle, M. C., Chattopadhyay, R., Kato, S., Fanta, P. T., Banks, K. C., Choi, I. S., Piccioni, D. E., Ikeda, S., Talasaz, A. H., Lanman, R. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0885 · Cited by 110

Targeting EGFR in Lung Cancer: Current Standards and Developments

Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

Chen, H.-J., Mok, T. S. K., Chen, Z. H., Guo, A., Zhang, X., Su, J., & Wu, Y.-L. L. C. (2009) · Pathology & Oncology Research · doi:10.1007/s12253-009-9167-8 · Cited by 107

Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation

Endo, H., Okami, J., Okuyama, H., Kumagai, T., Uchida, J., Kondo, J., Takehara, T., Nishizawa, Y., Imamura, F., Higashiyama, M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779ccf · Cited by 109

miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124

Gao, Y., Fan, X., Li, W., Wei, P., Deng, Y. L., & Fu, X. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.073 · Cited by 107

Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance

Boeckx, C., Baay, M. F. D., Wouters, A., Specenier, P. M., Vermorken, J. B., Peeters, M., & Lardon, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0013 · Cited by 110

Targeting MET Amplification as a New Oncogenic Driver

Kawakami, H., Okamoto, I., Okamoto, W., Tanizaki, J., Nakagawa, K., & Nishio, K. (2014) · Cancers · doi:10.3390/cancers6031540 · Cited by 107

The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils

Stammnitz, M. R., Coorens, T. H. H., Gori, K. C., Hayes, D., Fu, B., Wang, J., Martin-Herranz, D. E., Alexandrov, L. B., Baez‐Ortega, A., Barthorpe, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.013 · Cited by 107

Mechanisms of tumor resistance to EGFR-targeted therapies

Hopper-Borge, E. A., Nasto, R. E., Ratushny, V., Weiner, L. M., Golemis, E. A., & Astsaturov, I. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712590902735795 · Cited by 109

Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives

Norman, M. H., Liu, L., Lee, M., Xi, N., Fellows, I. M., D’Angelo, N. D., Dominguez, C., Rex, K. L., Bellon, S. F., Kim, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201330u · Cited by 106

E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

Nakagawa, T., Tohyama, O., Yamaguchi, A., Matsushima, T., Takahashi, K., Funasaka, S., Shirotori, S., Asada, M., & Obaishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01343.x · Cited by 106

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

Vivanco, I., Rohle, D., Versele, M., Iwanami, A., Kuga, D., Oldrini, B., Tanaka, K., Dang, J. H. T., Kubek, S., Palaskas, N. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911188107 · Cited by 108

Lung cancer in never smokers: Change of a mindset in the molecular era

Lee, Y. J., Kim, J.-H., Kim, S. I., Ha, S., Mok, T. S. K., Mitsudomi, T., & Cho, B. C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.013 · Cited by 107

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer

Halliday, P. R., Blakely, C. M., & Bivona, T. G. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0770-x · Cited by 111

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Xu, L., Kikuchi, E., Xu, C., Ebi, H., Ercan, D., Cheng, K. A., Padera, R. F., Engelman, J. A., Janne, P. A., Shapiro, G. I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3720 · Cited by 106

Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes

Yang, Z., & Tam, K. Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.22955 · Cited by 105

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases

Tan, Y. C., Krishnaswamy, S., Nandi, S., Kanteti, R., Vora, S., Onel, K., Hasina, R., Lo, F.-Y., El‐Hashani, E., Cervantes, G. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008972 · Cited by 104

Curcumin: Updated Molecular Mechanisms and Intervention Targets in Human Lung Cancer

Ye, M.-X., Li, Y., Yin, H., & Zhang, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13033959 · Cited by 108

METExon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations

Socinski, M. A., Pennell, N. A., & Davies, K. D. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00516 · Cited by 104

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

Toschi, L., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0071 · Cited by 104

Targeted Therapies for Lung Cancer

Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e701a · Cited by 106

The next tier of EGFR resistance mutations in lung cancer

Tumbrink, H. L., Heimsoeth, A., & Sos, M. L. (2020) · Oncogene · doi:10.1038/s41388-020-01510-w · Cited by 101

The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies

Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 109

Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells

Gao, W., Wang, M. L., Wang, L., Lu, H., Wu, S., Dai, B., Ou, Z., Zhang, L., Heymach, J. V., Gold, K. A., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju204 · Cited by 101

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Suda, K., Murakami, I., Katayama, T., Tomizawa, K., Osada, H., Sekido, Y., Maehara, Y., Yatabe, Y., & Mitsudomi, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1371 · Cited by 206

HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Yano, S., Wang, W., Li, Q., Yamada, T., Takeuchi, S., Matsumoto, K., Nishioka, Y., & Sone, S. (2011) · Current Signal Transduction Therapy · doi:10.2174/157436211795659928 · Cited by 3

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454

Occurrence of HER2 amplification in EGFR-mutant lung adenocarcinoma with acquired resistence to EGFR-TKIs.

Altavilla, G., Arrigo, C., Tomasello, C., Santarpía, M., Mondello, P., Benecchi, S., & Pitini, V. V. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8047 · Cited by 5

P3.13-14 Identification of Novel Mutations by High-Throughout Sequencing in T790M Wildtype/cMET Unamplified NSCLC with Acquired Resistance to EGFR TKIs

Li, C., Zhang, B., & Wang, C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.1854